GlassScriptPhysician profile
Lesley C Martin
NPI 1114900834
$5,816.26
in general payments reported to CMS, 2019-2025
48 companies · $1,057 in 2025
The $1,057 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,387 · 2020: $235 · 2021: $246 · 2022: $689 · 2023: $1,176 · 2024: $1,026 · 2025: $1,057.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,234 · Education: $25.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,233.76 |
| Education | $25.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $571.53 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $496.29 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $492.58 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Celgene Corporation | $434.32 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Astrazeneca Pharmaceuticals LP | $428.44 | 2022-2025 | Lynparza, Calquence, Tagrisso |
| E.R. Squibb & Sons, L.L.C. | $326.71 | 2019-2025 | Opdivo, Eliquis |
| Astellas Pharma US INC | $286.66 | 2019-2024 | Xospata, Padcev |
| Takeda Pharmaceuticals U.S.A., INC. | $217.29 | 2019-2025 | Iclusig, Ninlaro |
| Glaxosmithkline, LLC. | $203.71 | 2022-2025 | Zejula, Jemperli, Shingrix |
| Genentech USA, INC. | $195.38 | 2019-2024 | Tecentriq, Phesgo, Alecensa |
| Eisai INC. | $193.98 | 2019-2025 | |
| Amgen INC. | $161.62 | 2019-2023 | Lumakras |
| Seagen INC. | $153.05 | 2019-2023 | Tukysa |
| Janssen Biotech, INC. | $141.98 | 2019-2025 | Darzalex, Akeega, Balversa |
| Abbvie INC. | $137.33 | 2024-2025 |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agios Pharmaceuticals, INC. | $114.79 | 2019-2025 | Pyrukynd |
| Gilead Sciences, INC. | $84.53 | 2023-2025 | Trodelvy |
| Pharmacyclics LLC, An Abbvie Company | $80.09 | 2019-2023 | Imbruvica |
| Kite Pharma, INC. | $75.79 | 2019-2023 | |
| Daiichi Sankyo INC. | $69.15 | 2019-2025 | Enhertu |
| Incyte Corporation | $66.89 | 2019-2024 | Monjuvi |
| Octapharma USA, INC. | $61.67 | 2019-2020 | |
| Deciphera Pharmaceuticals INC. | $59.11 | 2023-2025 | Qinlock, Tgct |
| Lilly USA, LLC | $53.57 | 2025 | Verzenio, Jaypirca |
| Organon LLC | $52.65 | 2022 | |
| Jazz Pharmaceuticals INC. | $47.95 | 2023 | |
| Beigene USA, INC. | $41.15 | 2022-2023 | Brukinsa |
| Acrotech Biopharma INC. | $39.83 | 2021-2022 | |
| Exelixis INC. | $37.15 | 2022 | |
| Janssen Pharmaceuticals, INC | $37.09 | 2023-2024 | Xarelto |
| Servier Pharmaceuticals LLC | $33.36 | 2019-2024 | |
| Genzyme Corporation | $32.95 | 2023 | |
| Clovis Oncology, INC. | $32.62 | 2019-2021 | |
| Syndax Pharmaceuticals, INC. | $31.90 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $31.26 | 2025 | Libtayo |
| Tesaro, INC. | $30.52 | 2019 | |
| Emd Serono, INC. | $30.25 | 2019-2023 | Bavencio |
| Invivyd INC | $26.43 | 2025 | Pemgarda |
| Array Biopharma INC | $26.13 | 2024 | Mektovi, Lorbrena, Braftovi |
| Aveo Pharmaceuticals, INC. | $25.40 | 2023 | Fotivda |
| Sobi, INC | $24.95 | 2023 | |
| Foundation Medicine, INC. | $22.80 | 2023 | |
| Adaptive Biotechnologies Corporation | $19.17 | 2022 | |
| Tempus Ai, INC | $18.72 | 2025 | Xt Cdx |
| Aadi Bioscience, INC. | $18.38 | 2025 | Fyarro |
| Kyowa Kirin, INC. | $17.03 | 2019 | |
| Caris Mpi, INC. | $16.10 | 2025 | Mi Cancer Seek |
| Abbott Laboratories | $16.01 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lesley Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.